NYSE MKT to Suspend Trading of Provectus Biopharma (PVCT) Shares; Will Move to Delist

October 13, 2016 11:41 AM EDT
Get Alerts PVCT Hot Sheet
Trade PVCT Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

NYSE MKT LLC announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Provectus Biopharmaceuticals, Inc. (NYSE: PVCT) — ticker symbol PVCT —from the Exchange. Trading in the Company’s common stock on the NYSE MKT will be suspended immediately.

The Company has a warrant, which will also be delisted:

Ticker Symbol

Issue Description

PVCT WS

Warrants exercisable for one share of common stock par value $0.001 per share at an exercise price of $0.85 per share (Expiring August 30, 2021.)

NYSE Regulation has determined that the Company is no longer suitable for listing pursuant to Section 1003 of the NYSE MKT Company Guide, due to the abnormally low trading price of its common stock.

The Company has a right to a review of staff’s determination to delist the common stock and warrant by a committee of the Board of Directors of the Exchange. The NYSE MKT will apply to the Securities and Exchange Commission to delist the Company’s common stock and warrant upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff’s decision.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, Hot Corp. News, Trading Halts

Add Your Comment